24 November 2022>: Human Study
FLT3 Gene Mutations in Acute Myeloid Leukemia Patients in Northeast Thailand
Nang Ei Ei Aung 1BCD , Supawadee Yamsri 2ACDE* , Nattiya Teawtrakul 3B , Piyawan Kamsaen 4B , Supan Fucharoen 2DGDOI: 10.12659/MSMBR.937446
Med Sci Monit Basic Res 2022; 28:e937446
Table 2 Characteristics of patients with FMS-like tyrosine kinase 3 (FLT3)-tyrosine kinase domain (TKD) mutations.
Mutations | Characteristics of mutations* | Characteristics of patients | ||||||
---|---|---|---|---|---|---|---|---|
Amino acid change | FATHMM prediction | Type of mutation | Drug resistance | Age/sex | FAB subtype | WBC count (μL) | PB blast% | |
835GT – GT (c.2504A>T) | p.Asp835Val | Pathogenic (score 0.99) | Substitution – missense | Quizartinib | 39/F | AML-M3 | 70 660 | 5 |
49/F | AML-nonM3 | 12 140 | 9 | |||||
49/F | AML-nonM3 | 22 500 | 17 | |||||
15/F | AML-nonM3 | 10 580 | 0 | |||||
835AT – AT (c.2503G>C) | p.Asp835His | Pathogenic (score 0.99) | Substitution – missense | Sorafenib | 13/F | AML-M3 | 1370 | 17 |
836AT – AT (c.2508C>A) | p.Ile836= | Neutral (score 0.11) | Substitution – coding silent | n/a | 64/M | AML-nonM3 | 89 590 | 20 |
836AT – AT (c.2508C>G) | p.Ile836Met | Neutral (score 0.20) | Substitution – missense | n/a | 59/M | AML-nonM3 | 89 400 | 93 |
* From COSMIC database () []. n/a – not available. |